Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Sprott Uranium Miners ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Sprott Uranium Miners ETF trades at $42 (market cap $1.78B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 4.2× Sprott Uranium Miners ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Sprott Uranium Miners ETF for 62 Days on average.
| SYRE | URNM | |
|---|---|---|
Market Cap | $7.52B | $1.78B |
Volume | 1,441,031 | 1,008,269 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $108.92 | $83.99 |
52-Week Low | $22.18 | $42.42 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
URNM trades at $44.51, down 1.44% on the day, with a bearish technical signal from moving averages and oscillators. Recent news highlights uranium's role in AI energy demand and nuclear expansion, but financial ratios are unavailable. The ETF tracks uranium miners, with support at $43 and resistance at $46.
Long-term prospects are supported by nuclear energy growth and AI power needs, but short-term price volatility and lack of fundamental data pose risks. Investor sentiment is mixed, with bullish articles on uranium's future but technical indicators suggesting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
